Several months after turning down NHS funding for Novartis’ CGRP inhibitor Aimovig for migraine prevention, NICE has backed another drug in the class – Teva’s Ajovy – in draft guidance.
Ajovy is one of a group of calcitonin gene-related peptide (CGRP) class drugs that are coming to market. Novartis was first to market with its CGRP drug Aimovig (erenumab) in Europe, which was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback